amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences) for COVID-19

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 outpatients meta-analysis
ACTIV-2 (BRII-196 and BRII-198) unpublished NCT04518410		RCT	amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences)	placebo	COVID 19 outpatients	NA	418/419	suggested	suggested 95 % decrease in deaths suggested 78 % decrease in hospitalization or death

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 outpatients meta-analysis